Results 31 to 40 of about 15,139,370 (299)
Association between complaints and immune-related adverse events.
Association between complaints and immune-related adverse events.
Yuji Miyoshi (3172629) +5 more
core +1 more source
Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors.
Roser Calvo
doaj +1 more source
Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review
Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related ...
Alruwaii, Zainab I. +3 more
core +1 more source
Treatment Outcomes of Immune-Related Cutaneous Adverse Events [PDF]
PURPOSE The aim of the current study was to report the efficacy of topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed to checkpoint inhibitors in an uncontrolled cohort of patients referred to oncodermatology clinics.
Gregory S, Phillips +22 more
openaire +4 more sources
Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review
Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related ...
Elizabeth A. Montgomery +3 more
core +1 more source
Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series [PDF]
Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies.
Alfredomaria Lurati +5 more
core +2 more sources
Immune-related adverse events and the balancing act of immunotherapy [PDF]
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
Michael Conroy, Jarushka Naidoo
openaire +3 more sources
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle ...
Xiao-Hui Jia +9 more
doaj +1 more source
Immunotherapy for malignant tumors is a hot spot in current research and the treatment of cancer. The activation of programmed cell death receptor‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen 4 (CTLA)‐4 relevant signaling pathway can inhibit ...
Yue Li +10 more
doaj +1 more source
BackgroundImmune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs.MethodsWe described the case of a patient ...
Yizhang Hu +4 more
doaj +1 more source

